December 27, 2021 – The FDA has authorized EUA of Pfizer’s PAXLOVID™ for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The treatment includes nirmatrelvir, a novel main protease inhibitor originating in Pfizer’s laboratories, which was specifically designed to block the activity of the SARS-CoV-2 main protease, an enzyme that the coronavirus needs to replicate.